The drugmaker raised its 2022 forecast Thursday after its coronavirus treatment molnupiravir brought in almost
Analysts were expecting
One analyst said on a Thursday call with company leaders that some data shows the treatment Paxlovid from rival
Chief Financial Officer
She said data they have access to suggests that 500,000 people have used Lagevrio so far globally, and use has been particularly strong outside
Governments have been using and stockpiling both Lagevrio, which is also made by Ridgeback Biotherapeutics, and Paxlovid, which was shown to be more effective in clinical research, after the omicron surge of the virus filled hospitals earlier this year.
The treatments have been seen as a breakthrough in the fight to control the ongoing pandemic because they are effective and are easier for patients to use than other drugs that require injections or IV infusions.
The drugs are being used to treat patients most at risk of winding up in a hospital from the virus.
Both Lagevrio and Paxlovid must be used soon after COVID-19 symptoms appear, and
The treatments are free to patients in the
Not counting Lagevrio,
Overall,
Adjusted earnings, which exclude one-time items, totaled
Analysts expected, on average, earnings of
The company also said Thursday it was raising and narrowing its forecast for the year.
Analysts expect earnings of
Shares of
Follow
Copyright 2022 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission., source